HANSOH PHARMA (03692) has announced that its self-developed fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), HS-10504 tablets, has been approved by China's National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Designation program. The intended indication is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR C797S mutation following failure of prior EGFR-TKI therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments